News

Precigen Reports Q3 2024 Progress and Financial Insights

Precigen Reports Q3 2024 Progress and Financial Insights

Key Developments in Q3 2024

Precigen, Inc. (NASDAQ: PGEN) recently reported its financial results for the third quarter of 2024, along with critical business updates that highlight the company's strategic direction and innovative developments in gene and cell therapies.

Regulatory Progress and Clinical Updates

The company successfully completed a pre-BLA meeting with the FDA, achieving full alignment on the Biologics License Application (BLA) content, including pivotal chemistry, manufacturing, and controls (CMC) modules. This positions the company for a rolling BLA submission for PRGN-2012, an investigational therapy for recurrent respiratory papillomatosis (RRP) under the accelerated approval pathway.

Moreover, Precigen has initiated a confirmatory clinical trial for PRGN-2012, following FDA guidance, to commence prior to the BLA submission. The campaign for commercial and manufacturing readiness for PRGN-2012 is currently underway, aiming for a potential launch in 2025.

Strengthening Platforms for Future Growth

In addition to PRGN-2012, Precigen is gearing up for an end of Phase 1b meeting with the FDA in early 2025 to discuss PRGN-3006, a treatment for acute myeloid leukemia (AML). Data from preclinical studies on PRGN-3008, a next-generation UltraCAR-T therapy targeting CD19, was recently presented at a leading oncology conference, cementing its position as a competitive therapy for oncology and autoimmune diseases.

Helen Sabzevari, PhD, President and CEO of Precigen, highlighted the strategic reprioritization of resources to advance PRGN-2012 and emphasized continued innovations through their UltraCAR-T platform.

Financial Highlights of Q3 2024

During this quarter, Precigen reported an increase in selling, general, and administrative (SG&A) expenses by 7% compared to the previous year. This rise is mainly due to the heightened focus on advancing PRGN-2012 in preparation for its commercial launch. R&D costs saw a 2% decrease thanks to strategic resource allocation and streamlining operations.

The company closed a public offering of common stock with net proceeds of about $30.9 million, aiding its financial stability during this critical phase. However, net losses amounted to $24 million, compared to $19.8 million for the same period last year, attributed to investments in crucial therapies and workforce restructuring.

Pipeline and Future Directions

Precigen's ongoing work in the RRP field, along with its commitment to developing cutting-edge therapies like PRGN-2009 for HPV-associated cancers, showcases its dedication to harnessing innovative treatments to address pressing health challenges. The company remains focused on its confirmatory trials and is exploring partnerships that can enhance its capabilities while reducing financial burdens.

About Precigen

Precigen, Inc. (NASDAQ: PGEN) is a clinical-stage biopharmaceutical company dedicated to the development of innovative gene and cell therapies. With a focus on immuno-oncology, autoimmune disorders, and infectious diseases, the company aims to advance the next generation of targeted therapies that provide affordable biotherapeutics in a controlled manner. For more detailed information, potential partners and patients can visit Precigen's official website.

Frequently Asked Questions

What is the strategic focus of Precigen moving forward?

Precigen is concentrating on advancing therapies like PRGN-2012 for RRP and exploring partnerships to enhance its resource allocation during potential commercialization efforts.

What are PRGN-2012 and PRGN-3006?

PRGN-2012 is an investigational therapy for recurrent respiratory papillomatosis, while PRGN-3006 is a treatment targeting acute myeloid leukemia, both representing key advancements in Precigen's pipeline.

How did Precigen's financial performance compare year-on-year?

Precigen reported a net loss of $24 million in Q3 2024, compared to $19.8 million in Q3 2023, reflecting increased investment in R&D and workforce adjustments.

What recent data was presented for PRGN-3008?

Preclinical data for PRGN-3008, targeting CD19, indicated promising results that may position it as a best-in-class therapy, with potential applications in oncology and autoimmune diseases.

How significant is the FDA's involvement for Precigen?

The FDA's alignment on the BLA submissions and its ongoing guidance for clinical trials greatly supports Precigen's efforts to bring innovative therapies to market effectively.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 104

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
Nonprofit and Partners Gift Homes to Veterans

Updated Category News Views 87

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

Continue Reading
Purdue's xGTT: Pioneering a New Trust Standard in Tech

Updated Category News Views 150

A Bold New Benchmark in Tech Trust You've got to hand it to the folks at Purdue's Krach Institute—they're not dancing around the fringes but diving straight into the thick of it with their Global Trusted Tech Standard, or xGTT. This isn't just another checkbox for compliance nerds. The xGTT is all about building trust in technology that's woven with democratic values...

Continue Reading
CVRx Faces Legal Storm: Investors Grapple with Fallout

Updated Category News Views 150

CVRx in the Crosshairs: Legal and Operational Woes There's a storm brewing over at CVRx, Inc. (NASDAQ: CVRX), and it's pulling investors down a hell of a financial rabbit hole. You might think you're in the clear with a company like CVRx that boasts approved devices, but think again. Recent revelations have shown that even those with FDA stamps aren't immune to the...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 108

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Interactive Donor Recognition: Beyond GivingTuesday

Updated Category News Views 98

Crafting Stories That Endure You ever notice how some things just fade away after the holidays? Schools don't want their donor stories to go out like last year's tinsel. Rocket Alumni Solutions strikes right at the core of this concern. They recommend crafting donor recognition that lasts beyond GivingTuesday, by anchoring the story in the school's community. This isn't...

Continue Reading
Samuel Oschin Center Opens, Promising Wonder

Updated Category News Views 162

A Grand New Space for Space Well, here's a sight for sore eyes—California Science Center's Samuel Oschin Air and Space Center just swung its doors open wide, and boy, it's a beast of a place. Housing a spectacle like the Space Shuttle Endeavour in a vertical launch position, it's as if they've reached up and snagged a piece of the sky itself for their exhibits. They're...

Continue Reading
PangeAI and Sky Blue Transform Data Center Decisions

Updated Category News Views 117

Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...

Continue Reading
Backdoor Reference Checks: A Hiring Minefield?

Updated Category News Views 157

What's Really Happening with Job References? Every job seeker has been there, right? You're all set, resume polished to a shine, references lined up like a choir ready to sing your praises, and then bam—you hear that employers are contacting folks you never listed. A new report from Zety highlights this eyebrow-raising trend, and it's got us all questioning the value...

Continue Reading
Optikos Secures CMMC Level 2, Eyeing Defense Market

Updated Category News Views 116

Optikos Levels Up with CMMC Certification In a world where cybersecurity threats are lurking around every corner, Optikos has just joined the rarefied ranks of the top 1% of U.S. defense suppliers by grabbing the CMMC Level 2 certification. Let me tell you, this isn't just some shiny badge for show; it's a gateway to big defense contracts. Crunching the Numbers Of the...

Continue Reading

Top 5 Most Recently Viewed Articles

IHS Holding's Deal: Fair Price or Insider Play?

Updated Category News Views 170

IHS Holding (NYSE: IHS) just got slapped with an investigation from Ademi LLP over possible breaches of fiduciary duty in their recent $6.2 billion transaction with MTN Group Limited. Let’s break this down—traders are already fuming about what’s cooking under the surface. Insider Gains: Who Wins? The crux here is that shareholders will pocket a measly $8.50 per...

Continue Reading
PLAY Airlines Achieves Record Load Factor and Revenue Growth

Updated Category News Views 248

PLAY Airlines Reports Record-Breaking Load Factor for November PLAY Airlines has announced that it carried an impressive 99,393 passengers in the month of November, showcasing its operational efficiency and strategic adaptations. Although this is a decrease from the 107,236 passengers flown in the same month in the previous year, this is largely attributed to a 17%...

Continue Reading
Tempus Collaborates with Northwestern Medicine to Enhance AI Use in Care

Updated Category News Views 122

Tempus Teams Up with Northwestern Medicine to Transform Healthcare Tempus, a frontrunner in the realm of artificial intelligence and precision medicine, has announced a significant collaboration with Northwestern Medicine, noted for being a leading integrated academic health system. This partnership is tailored to investigate the practical applications of artificial...

Continue Reading
Investor Insights: May's Most Influential Announcements

Updated Category News Views 28

The Sky's the Limit with United's Spirit Chase Kicking off May with a twist, United Airlines threw out a bone to Spirit Airline's distressed travelers. For those whose flights were axed, United dangled capped-price tickets as a lifeline. Maybe it's about garnering goodwill, maybe it's swiping market slice—either way, United's move isn't just about customer care....

Continue Reading
Fountainful Partners with SFSG for Timeless Bench Installation

Updated Category News Views 179

Fountainful Partners with Sculpture Garden for Bench Installation Fountainful is thrilled to announce its collaboration with the Saint Francis Sculpture Garden (SFSG) on a long-term bench installation project. When discussions began about replacing outdated wooden benches, it sparked excitement within Fountainful. Donna Shatter, a managing partner of Fountainful,...

Continue Reading